Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome
Starting soon · Not applicable · Has a placebo group
Conditions studied: Allergic Asthma
In brief
Allergic asthma is a common allergic disease characterized by a protracted disease course and recurrent episodes, which severely impairs patients' physical and mental health. There is a paucity of high-quality clinical evidence in the treatment of allergic asthma with traditional Chinese medicine (TCM). This study will enroll patients who are persistent allergic asthma with spleen deficiency and dampness accumulation syndrome. A multicenter, randomized, double-blind, placebo-controlled trial design is adopted. The experimental group will receive Modified Shenling Baizhu Powder in addition to Budesonide and Formoterol Fumarate Powder for Inhalation, while the control group will receive a placebo in addition to the same inhalation therapy. Both groups will undergo an 8 week of treatment followed by a 12 week of follow-up. The primary outcome is Asthma Control Test scores, and the secondary outcomes include acute exacerbations, Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire scores, pulmonary function, airway inflammatory markers, clinical symptom scores, serum inflammatory markers, immune markers, and use of controller medications.
Key facts
- Study ID
- NCT07352488
- Run by
- Henan University of Traditional Chinese Medicine
- People needed
- 400
- Starts
- 2026-01-15
- Expected to finish
- 2028-03-31
- Last updated by the study team
- 2026-01-20
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients who are persistent allergic asthma.
- Patients who meet the diagnostic criteria for the spleen deficiency and dampness accumulation syndrome.
- Patients who are aged between 18 and 80 years.
- Patients who voluntarily accept the treatment and sign the informed consent form.
You may not qualify if…
- Patients who have chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis , active pulmonary tuberculosis, or pulmonary embolism, etc.
- Patients who have severe cardiovascular or cerebrovascular diseases.
- Patients who have severe liver or kidney diseases.
- Patients who have a history of tumor.
- Patients who have cognitive impairment or psychiatric disorders.
- Patients who are pregnant or breastfeeding.
- Patients who are allergic to medication(s) used.
- Patients who participated in another clinical trial within one month prior to enrollment.
Where it is running
- The First Affiliated Hospital of Henan University of Chinese Medicine — Zhengzhou, Henan, China
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine — Jinan, Shandong, China
- Hangzhou Third People's Hospital — Hangzhou, Zhejiang, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.